Remicade gets first green light for paediatric ulcerative colitis in Canada
This article was originally published in Scrip
Executive Summary
Health Canada is the first regulatory authority to approve Johnson & Johnson's Remicade (infliximab) for ulcerative colitis in children. The approval marks the first biologic approved for this indication, says the company.